	FORM 1449*
	E is
	38
0	8 2000 g)

INFORMATION DISCLOSURE STATEMENT

IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 8279.829USWO

Application Number:

10/526858

Applicant: HIDAKA et al.

Filing Date: March 2, 2005

Group Art Unit: 1618

DEMINANT O		Į	U.S. PATENT DOCUM	ENTS				
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING IF APPRO		
		FO	DESCRIPTION DATES TO POST	INVENITO			·	
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSL	ATION	
	DOCOMENT NO.		COUNTRI	CLASS	30DCLA33	YES	NO	
			·····					
	ОТНЕ	R DOCUMENT	S (Including Author, Title	e, Date, Pertiner	it Pages, Etc.)			
/S.G./		TANAKA et al. "Isolation of cDNAs Encoding Cellular Drug-Binding Proteins using a Novel Expression Cloning Procedure: Drug-Western". <i>Molecular Pharmacology</i> , Vol. 55, No. 2, pp. 356-363 (1 Feb. 1999), XP-002192762.						
/S.G./	KATOH et al. "HMN-214, a Novel Anti-tumor Sulfonamide Compound". Proceedings of the Annual Meeting of the American Association for Cancer Research, Vol. 38, No. 473, p. 473, (12 April 1997), XP-001061737.							
/S.G./	Compound	KATOH et al. "Mode and Mechanisms of Cell Death Induced by HMN-214, a Novel Anti-tumor Sulfonamide Compound". Proceedings of the Annual Meeting of the American Association for Cancer Research, Vol. 39, p. 225 (28 March 1998), XP-001061702.						
/S.G./	formation :	MEDINA-GUNDRUM et al. "HMN-176 exhibits marked anticancer activity in ex-vivo human tumor colony formation assay. Proceedings of the Annual Meeting of the American Association for Cancer Research, Vol. 43, pp. 79-80 (I March 2002), XP-001538626.						
/S.G./	CALABRE 1225-1232	CALABRESI et al. "Chemotherapy of Neoplastic Diseases". <u>Pharmacological Basis of Therapeutics</u> , Section 10, pp. 1225-1232 (I Jan. 1996), XP-002973969.						

52835
Customer Number

EXAMINER	/Shirley Gembeh/	DATE CONSIDERED	04/09/2009
			5 // CC/ MCCC

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.